Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- Drug Pricing Tomorrow: JPA’s Abe Eyes Longer-Term Trial for Key Pricing Premium
July 28, 2015
- No. of Sales Reps Decreases by over 1,000 in FY2014
July 28, 2015
- Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
- Hodanren Demands Abolishment of Innovation Premium
July 17, 2015
- US, European Lobbies Issue Joint Statement Opposing Annual Price Revisions
July 16, 2015
- Drug Pricing Tomorrow: Kenporen Veep Wants Holistic Drug Policy in FY2016 Reform
July 15, 2015
- Japan CRO Association Looking at Ways to Radically Reform Monitoring through Use of IT
July 15, 2015
- Sales by JCROA Member Companies Rise 4.9% to 143.5 Billion Yen in FY2014
July 15, 2015
- “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
- JPMA Sacks Hasegawa as Vice President after Business Improvement Order
July 3, 2015
- FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
- JPMA Announces New Fair Competition Guidelines
July 2, 2015
- JGSM Policy Proposal Calls for Generic Volume Target of 80% by End of FY2020
July 1, 2015
- Dr Takaku Clinches Sixth Term as JAMS Chief
June 26, 2015
- Chiba Univ. Hospital to Raise Generic Drug Use Rate to 80% after July: Director-General
June 24, 2015
- FPMAJ Subcommittee Calls for Caution on “Simply Adding 2% to NHI Prices in Conjunction with Sales Tax Hike” in FY2017 Revision
June 16, 2015
- FPMAJ to Present Evidence Showing Revenue from Premium for New Drug Development Is Being Invested in New Drugs
June 16, 2015
- Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
June 15, 2015
- EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…